- Home
- ALLR vs CRIS Comparison
ALLR vs CRIS Comparison
Compare ALLR & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- CRIS
- Stock Information
- Founded
- ALLR 2004
- CRIS 2000
- Country
- ALLR United States
- CRIS United States
- Employees
- ALLR N/A
- CRIS N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALLR Health Care
- CRIS Health Care
- Exchange
- ALLR Nasdaq
- CRIS Nasdaq
- Market Cap
- ALLR 20.2M
- CRIS 18.6M
- IPO Year
- ALLR N/A
- CRIS 2000
- Fundamental
- Price
- ALLR $1.23
- CRIS $1.25
- Analyst Decision
- ALLR Strong Buy
- CRIS Strong Buy
- Analyst Count
- ALLR 1
- CRIS 2
- Target Price
- ALLR $9.25
- CRIS $16.50
- AVG Volume (30 Days)
- ALLR 262.6K
- CRIS 75.7K
- Earning Date
- ALLR 11-14-2025
- CRIS 11-06-2025
- Dividend Yield
- ALLR N/A
- CRIS N/A
- EPS Growth
- ALLR N/A
- CRIS N/A
- EPS
- ALLR N/A
- CRIS N/A
- Revenue
- ALLR N/A
- CRIS $11,650,000.00
- Revenue This Year
- ALLR N/A
- CRIS $2.72
- Revenue Next Year
- ALLR N/A
- CRIS $8.27
- P/E Ratio
- ALLR N/A
- CRIS N/A
- Revenue Growth
- ALLR N/A
- CRIS 13.56
- 52 Week Low
- ALLR $0.61
- CRIS $1.02
- 52 Week High
- ALLR $2.35
- CRIS $4.70
- Technical
- Relative Strength Index (RSI)
- ALLR 40.99
- CRIS 24.41
- Support Level
- ALLR $1.09
- CRIS $1.21
- Resistance Level
- ALLR $1.45
- CRIS $1.49
- Average True Range (ATR)
- ALLR 0.09
- CRIS 0.08
- MACD
- ALLR -0.02
- CRIS -0.02
- Stochastic Oscillator
- ALLR 37.42
- CRIS 6.38
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.